How has Tango Therapeutics's payments of stock issuance costs changed year-over-year?

Tango Therapeutics's payments of stock issuance costs increased by 5866.7% year-over-year, from $9K to $537K.

Tango Therapeutics TNGX Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Essential Properties Realty TrustEPRT

$152K-35.6%

Tango TherapeuticsTNGX

$537K+5,867%

American Healthcare REITAHR

$1.35M+128%

Solaris Energy InfrastructureSEI

$0-100%

CG OncologyCGON

$47K-79.7%

NNN REITNNN

$100K+17.6%

Other financials

Income statement

See full

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

See full

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

See full

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

See full

Market cap$4.55B+1,915%

Profitability

See full

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

See full

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tango Therapeutics's payments of stock issuance costs?: Tango Therapeutics (TNGX) reported payments of stock issuance costs of $537K in Q1 2026.
How has Tango Therapeutics's payments of stock issuance costs changed year-over-year?: Tango Therapeutics's payments of stock issuance costs increased by 5866.7% year-over-year, from $9K to $537K.